| Bioactivity | Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer[1][2][3]. |
| In Vivo | Labetuzumab govitecan (总共 1.0 mg，腹腔注射) 可延长 GW-39 肺转移小鼠模型的中位生存期[2]。Labetuzumab govitecan (25 mg/kg，腹腔注射，每周两次，持续 4 周) 可延长皮下 LS174T 异种移植裸鼠的中位生存期[2]。 Animal Model: |
| Name | Labetuzumab govitecan |
| CAS | 1469876-18-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346. [2]. Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015 Jun 1;12(6):1836-47. [3]. Criscitiello C,et al. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 Jan 28;14(1):20. |